According to this new study, the global monoclonal antibodies in veterinary health market size is expected to reach USD 2,629.6 million by 2030. The report gives a detailed insight into current market dynamics and provides an analysis of future market growth
DUBLIN--(BUSINESS WIRE)--Nov 11, 2022--
According to this new study, the global monoclonal antibodies in veterinary health market size is expected to reach USD 2,629.6 million by 2030. The report gives a detailed insight into current market dynamics and provides an analysis of future market growth.
The industry is expanding due to the development of novel monoclonal antibodies and increasing the cost of pets, treatments for allergic conditions, and increasing incidences of cancer, especially in dogs. Additionally, it is anticipated that awareness of advanced veterinary therapeutic options is likely to complement market growth.
The main drivers for market growth are the rising prevalence of atopic dermatitis and the rising rate of pet adoption. Additionally, the growing demand for therapeutic antibodies for the treatment of dogs' allergy diseases also contributes to the industry expansion.
The COVID-19 lockdowns and supply chain disruptions had less of an impact on the animal health industry economy than on other industries. In contrast, traditional practices generate a majority of their revenues from selling their high-margin products, such as pharmaceuticals.
Monoclonal Antibodies In Veterinary Health Market Report Highlights
Based on the animal type, dogs segment generated the largest share in 2021. The rising acceptance of pet insurance due to the increasing prevalence of numerous chronic diseases in animals is one of the major factors driving industry expansion
The prevalence of dermatological conditions such as allergic dermatitis and flea-and-tick-related disorders is predicted to rise. Some of the most often diagnosed dermatological diseases include seborrheic dermatitis, surface pyoderma, allergies, and otitis externa.
North America accounted for the largest revenue share in 2021. This is due to a number of initiatives from the public and private sectors, as well as the growing acceptance of pet insurance. Key industry participants in these regions are contributing to the revenue expansion.
Drivers and Opportunities
Rising pet owner concerns and expanding pet insurance
Rising importance of therapeutic monoclonal antibodies
Restraints and Challenges
Increase in the cost of pet healthcare
adivo GmbH
Bayer Animal Health
Boehringer Ingelheim GmbH
Elanco
Indian Immunologicals Ltd.
Invetx
Kindred Biosciences Inc.
Merck & Co. Inc
Nextmune
Virbac
Zoetis
The publisher has segmented the monoclonal antibodies in veterinary health market report based on animal type, application, end-use, and region:
Monoclonal Antibodies In Veterinary Health, Animal Type Outlook (Revenue - USD Million, 2018 - 2030)
Dogs
Others
Monoclonal Antibodies In Veterinary Health, Application Outlook (Revenue - USD Million, 2018 - 2030)
Dermatology
Pain
Others
Monoclonal Antibodies In Veterinary Health, End-Use Outlook (Revenue - USD Million, 2018 - 2030)
Veterinary Hospitals
Others
Monoclonal Antibodies In Veterinary Health, Regional Outlook (Revenue - USD Million, 2018 - 2030)
North America
U.S
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH VETERINARY OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/11/2022 12:20 PM/DISC: 11/11/2022 12:21 PM
http://www.businesswire.com/news/home/20221111005471/en